Summary of Significant Accounting Policies - Addtional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Significant Accounting Policies [Line Items]
Other Intangible Assets, Net		$ 1,250,000
Other Finite-Lived Intangible Assets, Gross		2,500,000
Research and Development	$ 3,020,027	1,630,439	$ 1,518,885
Cash	8,854,507	13,858,798	3,551,832	$ 534,046
Depreciation	41,137	10,284	0
Amortization	$ 160,625	$ 160,625	$ 160,625
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,078,611	4,734,861	4,848,298
Warrant
Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	10,000	10,000	10,000
Furniture
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Fixtures
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Equipment
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Jp Morgan Chase Bank
Significant Accounting Policies [Line Items]
Cash, FDIC Insured Amount	$ 8,600,000	$ 13,600,000
Federal Deposit Insurance	250,000
Cash		13,900,000
Md Anderson
Significant Accounting Policies [Line Items]
Other Intangible Assets, Net	1,100,000
Other Finite-Lived Intangible Assets, Gross	2,500,000
Amortization of Intangible Assets	1,400,000
License Expenses		100,000
Clinical Trial Expense		116,000
License Maintenance Fees		50,000
Research and Development		67,000
Technology Cost Paid In cash	$ 836,200
Technology Cost Paid In Shares	3,138,889
Technology Cost Paid In Shares Value	$ 2,350,000
Technology Impairment Charge	690,000
Technology Amortisation Monthly	160,000
Research and Development Costs Expenses	$ 3,000,000
Equity Method Investment, Ownership Percentage	5.00%
Md Anderson | Research and Development Expense
Significant Accounting Policies [Line Items]
Cash paid to MD Anderson Cancer Center for expenses		197,000	$ 116,000
Related Party
Significant Accounting Policies [Line Items]
License Expenses			64,000
Clinical Trial Expense			52,000
License Maintenance Fees			50,000
Research and Development	$ 0	196,661	115,705
Annual Maintenance Fee			$ 14,000
Related Party | Research and Development Expense
Significant Accounting Policies [Line Items]
Sirna Patent Technology License		$ 31,000